Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim Almquist

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
CPT: Pharmacometrics & Systems Pharmacology|May 22, 2020
Model-Based Analysis Reveals a Sustained and Dose-Dependent Acceleration of Wound Healing by VEGF-A mRNA (AZD8601)Joachim Almquist, S Michaela Rikard, Maria Wågberg, et al.
Cellular and Molecular Bioengineering|July 22, 2021
Mathematical Model Predicts that Acceleration of Diabetic Wound Healing is Dependent on Spatial Distribution of VEGF-A mRNA (AZD8601)S Michaela Rikard, Paul J Myers, Joachim Almquist, et al.
British Journal of Clinical Pharmacology|August 30, 2025
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthmaAnna Lundahl, Rod Hughes, Joachim Almquist, et al.
British Journal of Clinical Pharmacology|May 1, 2024
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trialPhilip Ambery, Grzegorz Zajac, Joachim Almquist, et al.
American Journal of Respiratory and Critical Care Medicine|August 19, 2020
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in AsthmaIoannis Psallidas, Vibeke Backer, Piotr Kuna, et al.
Iscience|June 20, 2025
A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055Xiao-Hong Zhou, Susanne Prothon, Engin Liathdale, et al.
Molecular Genetics and Genomics : MGG|April 15, 2014
Bridging the gaps in systems biologyMarija Cvijovic, Joachim Almquist, Jonas Hagmar, et al.
Clinical and Translational Science|October 24, 2023
AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety studyJacob M van Laar, Alejhandra Lei, Mary Safy-Khan, et al.
The Lancet. Rheumatology|January 23, 2024
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trialsTove Hegelund Myrbäck, Susanne Prothon, Karl Edman, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
CPT: Pharmacometrics & Systems Pharmacology|May 22, 2020
Model-Based Analysis Reveals a Sustained and Dose-Dependent Acceleration of Wound Healing by VEGF-A mRNA (AZD8601)Joachim Almquist, S Michaela Rikard, Maria Wågberg, et al.
Cellular and Molecular Bioengineering|July 22, 2021
Mathematical Model Predicts that Acceleration of Diabetic Wound Healing is Dependent on Spatial Distribution of VEGF-A mRNA (AZD8601)S Michaela Rikard, Paul J Myers, Joachim Almquist, et al.
British Journal of Clinical Pharmacology|August 30, 2025
AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthmaAnna Lundahl, Rod Hughes, Joachim Almquist, et al.
British Journal of Clinical Pharmacology|May 1, 2024
The effect of AZD9567 vs. prednisolone on glycaemic control in patients with type 2 diabetes mellitus: Results from a phase 2a clinical trialPhilip Ambery, Grzegorz Zajac, Joachim Almquist, et al.
American Journal of Respiratory and Critical Care Medicine|August 19, 2020
A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in AsthmaIoannis Psallidas, Vibeke Backer, Piotr Kuna, et al.
Iscience|June 20, 2025
A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055Xiao-Hong Zhou, Susanne Prothon, Engin Liathdale, et al.
Molecular Genetics and Genomics : MGG|April 15, 2014
Bridging the gaps in systems biologyMarija Cvijovic, Joachim Almquist, Jonas Hagmar, et al.
Clinical and Translational Science|October 24, 2023
AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety studyJacob M van Laar, Alejhandra Lei, Mary Safy-Khan, et al.
The Lancet. Rheumatology|January 23, 2024
Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trialsTove Hegelund Myrbäck, Susanne Prothon, Karl Edman, et al.
Pageof 3